EX02 CAR-T cells for advanced pancreatic or bile duct cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental therapy that uses your own immune cells (T cells) that have been modified in a lab to recognize and attack your cancer. It is for people with advanced pancreatic or bile duct cancer that has not responded to standard treatments. The goal is to see if this cell therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic or bile duct cancer that cannot be removed by surgery or has spread to other parts of the body.
- You have already tried one or two lines of standard chemotherapy and either it didn't work, or you couldn't tolerate it, or the cancer came back.
- Your tumor or fluid in your abdomen must test positive for a marker called EX02 (the study team will check this with a biopsy or fluid sample).
- You are 18 years or older.
- You are generally well enough to carry out daily activities (ECOG performance status 0 or 1).
- You have adequate blood, kidney, liver, heart, and lung function, as determined by standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests an experimental cell therapy called BGT007 for people with advanced pancreatic or colorectal cancer that has not responded to standard treatments. The therapy uses your own immune cells, which are collected, modified, and given back to you to fight the cancer.
This trial tests a new treatment called EX02 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses your own immune cells, modified to target a specific marker on leukemia cells, to help fight the cancer.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to target a protein (Claudin18.2) found on some stomach and pancreatic cancer cells. The goal is to see if these specially designed cells can shrink tumors and slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.